The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Market Size Of The Peripheral Neuropathy Market In 2026 And What Value Is Projected For 2030?
The peripheral neuropathy market size has seen rapid expansion in recent years. Its valuation is set to rise from $4.59 billion in 2025 to $5.17 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.7%. Historically, the market’s growth has been fueled by factors including the high prevalence of diabetic neuropathy, increasing chemotherapy use, limited targeted therapies, reliance on conventional analgesics, and a lack of effective early diagnosis tools.
The peripheral neuropathy market is poised for significant expansion, with projections indicating it will reach $7.98 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.5%. This anticipated growth is driven by advancements in nerve stimulation therapies, the increasing adoption of physical therapy and non-pharmacological treatments, a growing availability of topical and systemic medications, the rising use of online pharmacies and telemedicine, and the expansion of specialized clinics and ambulatory centers. Key trends shaping the forecast period involve the increasing adoption of AI-based diagnostic tools for peripheral neuropathy, enhanced integration of big data and cloud solutions in patient monitoring, a growing application of genomics and precision medicine for peripheral neuropathy treatment, the increasing deployment of IoT-enabled wearable devices for nerve health, and the rising implementation of Industry 4.0 technologies within neuropathy treatment devices.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16507&type=smp
Which Growth Drivers Are Contributing To The Progress Of The Peripheral Neuropathy Market?
The increasing incidence of diabetes is anticipated to fuel the expansion of the peripheral neuropathy market in the future. Diabetes is defined as a chronic health issue marked by elevated blood glucose levels, resulting from the body’s impaired capacity to generate or efficiently utilize insulin. The growing occurrence of diabetes is largely attributable to elements like higher obesity rates, inactive lifestyles, and demographic shifts towards older populations. Diabetes has the potential to induce peripheral neuropathy through nerve damage caused by extended periods of high blood sugar, manifesting as symptoms such as discomfort, pricking sensations, and loss of feeling in the limbs. Proper management of blood sugar is vital to avert or impede the advancement of this complication. As an illustration, the International Diabetes Federation, a Belgium-based diabetes research organization, reported in 2024 that the global population of adults aged 20 to 79 years diagnosed with diabetes is expected to rise considerably from approximately 589 million in 2024 to 853 million by 2050, indicating a 45% increase. Consequently, the increasing prevalence of diabetes is propelling the growth of the peripheral neuropathy market.
What Are The Key Segments Of The Peripheral Neuropathy Market?
The peripheral neuropathy market covered in this report is segmented –
1) By Type: Chemotherapy-Induced, Diabetic, Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS Associated), Idiopathic
2) By Diagnosis: Blood Test, Biopsy, Imaging, Other Diagnosis
3) By Treatment: Medications, Antidepressants, Anti-Seizure Medication, Pain Reliever, Topical Treatment, Therapies, Nerve Stimulation, Plasma Exchange, Physical Therapy, Other Treatments
4) By End-User: Hospitals, Clinics, Ambulatory Centers
Subsegments:
1) By Chemotherapy-Induced: Taxane-Induced Peripheral Neuropathy, Platinum-Based Drug-Induced Neuropathy, Other Chemotherapy-Induced Neuropathies
2) By Diabetic: Type 1 Diabetes-Induced Peripheral Neuropathy, Type 2 Diabetes-Induced Peripheral Neuropathy
3) By Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS) Associated: HIV-Associated Peripheral Neuropathy, AIDS-Related Peripheral Neuropathy
4) By Idiopathic: Acute Idiopathic Neuropathy, Chronic Idiopathic Neuropathy
What Trends Are Advancing Progress In The Peripheral Neuropathy Market?
Major companies within the peripheral neuropathy market are actively developing sophisticated solutions, including point-of-care devices, to enhance the diagnosis and management of this condition. A point-of-care peripheral neuropathy quantitative screening test functions as a diagnostic instrument for the quick identification of nerve damage in individuals’ extremities, particularly in those with diabetes. For instance, in January 2023, NeuroMetrix Inc., a US-based non-invasive medical device manufacturer, unveiled the DPNCheck 2.0 point-of-care device specifically for detecting peripheral neuropathy. This device utilizes nerve conduction technology to identify the systemic degeneration of peripheral nerves, which can lead to debilitating conditions such as diabetic peripheral neuropathy (DPN). It enables rapid patient screening through the quantitative measurement of peripheral nerve function, positioning it as a more efficient and accurate tool compared to traditional methods like monofilament and tuning fork tests.
Who Are The Leading Companies Operating In The Peripheral Neuropathy Market?
Major companies operating in the peripheral neuropathy market are Pfizer Inc., Merck and Co. Inc., Novartis AG, Bristol Myers Squibb Co, AstraZeneca Plc, Abbott Laboratories, Eli Lilly and Co., Daiichi Sankyo Co. Ltd., Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Cadila Pharmaceuticals Ltd., Dr. Reddy’s Laboratories, Cipla Ltd., Apotex Inc, Hikma Pharmaceuticals PLC, Lupin Limited, Grunenthal GmbH, Lexicon Pharmaceuticals, Johnson and Johnson, Teva Pharmaceutical Industries Ltd, Sanofi, GSK plc
Read the full peripheral neuropathy market report here:
https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report
What Are The Leading Geographic Regions In The Peripheral Neuropathy Market?
North America was the largest region in the peripheral neuropathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peripheral neuropathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Peripheral Neuropathy Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=16507&type=smp
Browse Through More Reports Similar to the Global Peripheral Neuropathy Market 2026, By The Business Research Company
Tendonitis Treatment Global Market Report
https://www.thebusinessresearchcompany.com/report/tendonitis-treatment-global-market-report
Negative Pressure Wound Therapy Global Market Report
Pruritus Therapeutic Global Market Report
https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model